Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – Here’s What Happened

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s share price gapped down before the market opened on Monday . The stock had previously closed at $17.15, but opened at $16.25. Telix Pharmaceuticals shares last traded at $16.22, with a volume of 18,490 shares.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TLX. Wedbush restated an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Thursday, June 12th. William Blair reaffirmed an “outperform” rating on shares of Telix Pharmaceuticals in a report on Wednesday, March 12th.

Telix Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.66 and a current ratio of 2.78. The company has a 50 day simple moving average of $17.05 and a 200 day simple moving average of $16.95.

Institutional Investors Weigh In On Telix Pharmaceuticals

A hedge fund recently bought a new stake in Telix Pharmaceuticals stock. Private Advisor Group LLC bought a new stake in Telix Pharmaceuticals Limited (NASDAQ:TLX) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,140 shares of the company’s stock, valued at approximately $170,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.